The treatment regimen for BC depends primarily on the level of the estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor-2 (HER-2) and Ki-67 in tumor patients. This evidence concerns the gene ESR1 and neoplasm.